Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Thyroid Neoplasms 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × Biopsy, Large-Core Needle × Clear all
NCT04309136 2021-04-01

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Fudan University

Phase 2 Unknown
13 enrolled
Head & Neck

Thyroid Neoplasms

NCT04612894 2020-11-03

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Fudan University

Phase 2 Unknown
31 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡